Mesothelioma Progression-Free Survival Does Not Improve With Anetumab Ravtansine
Median overall survival increased from 10.1 months with anetumab ravtansine to 11.6 months with vinorelbine.
Median overall survival increased from 10.1 months with anetumab ravtansine to 11.6 months with vinorelbine.
Dacomitinib improved progression-free survival in patients with non-small cell lung cancer.
ROS1 and ALK rearrangements in patients with non-small cell lung cancer may predict different metastasis distributions at diagnosis.
Valuable information regarding patients’ life expectancy can be collected through neutrophil-lymphocyte ratio biomarkers.
The randomzied, phase 3 CONVERT trial examined 547 patients with small-cell lung cancer.
Results showed that proton-beam therapy in small-cell lung cancer can be safe in combined modality therapy.
Timing might affect the results of an EGFR mutation-frequency circulating tumor DNA test among patients with advanced non-small cell lung cancer.
The FDA approved osimertinib for treatment of EGFR T790M mutation positive non-small cell lung cancer.